Attitudes to predictive DNA testing for familial adenomatous polyposis were documented in 62 affected adults. Patient views on prenatal testing and termination ofpregnancy for this disorder were sought, as were opinions on the most suitable age to offer predictive testing for at risk children and the most appropriate age to begin screening. While 15 (24%) of those questioned stated that they would proceed to termination of pregnancy if a prenatal test indicated that the unborn baby was affected, in clinical practice no one has yet requested this option. Six (10%) people who had refrained from having children for fear ofpassing on the polyposis gene felt that the arrival of prenatal testing would enable them to consider planning a family. The majority of patients (93%) said they would like their children tested by DNA analysis at birth or in infancy, but felt that 10 to 12 years was the most appropriate time to discuss the diagnosis with the child. (J Med Genet 1996;33:540-543) 
Like many other autosomal dominant disorders, however, the clinical course of this illness is highly variable both within and between affected families. Some patients may experience several of the extracolonic complications mentioned above, while in others the effect of the disorder on their everyday lives may be minimal. While premature death in FAP is not inevitable, a recent life table analysis showed that FAP patients have a three fold relative risk of dying early compared to age and sex matched controls in the general population, even when screened and kept under close medical surveillance. 5 Before the late 1980s, at risk subjects were screened for rectosigmoid adenomas from the age of 10 to 16 years by regular sigmoidoscopy. Recently, it has been discovered that approximately 80% of affected people have a characteristic retinal pigmentation (CHRPE), and in some families this also can serve as a useful diagnostic marker. 6 The cloning of the gene responsible for FAP on chromosome 5q2 l,7 designated the APC gene, now means that in a high percentage of cases presymptomatic and even prenatal diagnosis can be offered using either linkage or mutational analysis.89 Two important questions can now be addressed. What do people with FAP think is the best age to offer predictive DNA testing for FAP in their at risk children? How acceptable is prenatal testing and selective termination of pregnancy for FAP for couples at risk of having affected children?
The answers to these questions will undoubtedly be influenced by psychological factors, perception of disease severity, and philosophical, personal, and religious attitudes to predictive DNA testing and termination of pregnancy. In turn, the perception of the severity of the disease and its subjective effects are likely to be strongly affected by the Reasons volunteered for opting for prenatal testing and termination were as follows. Six patients who had previously refrained from having children for fear ofpassing on the polyposis gene felt that the option of prenatal testing would enable them to consider planning a family, which they would otherwise not have done.
Six patients who had affected children stated that they felt very guilty about passing on the polyposis gene, and felt that had the prenatal option been available a great deal of unnecessary suffering might have been prevented.
Three patients who had children of unknown disease status said that they were very worried about the possibility of passing on the faulty gene, and felt that prenatal testing could have removed this chronic source of worry from their lives.
ATTITUDE TO AGE AT WHICH PREDICTIVE TESTING SHOULD BE PERFORMED IN THEIR CHILDREN
A total of 58/62 stated that they would like their children tested at birth, 1/62 at 10 years, and 3/62 at puberty.
PATIENT OPINION ON THE MOST SUITABLE AGE TO INTRODUCE THE SUBJECT OF POLYPOSIS TO THEIR CHILDREN
A total of 51/62 patients discussed this issue. The results are summarised in table 2.
Discussion
People with FAP may wish to know the results of their children's predictive tests, in order to spare those found to be at low risk unnecessary screening procedures and to relieve personal guilt and uncertainty. Adults at risk of developing FAP are clearly concerned about their own risk of developing cancer, and this may explain the high uptake of DNA testing in this group, which at St Mark's Hospital approaches 100%. By comparison, the uptake of predictive testing in Huntington's disease (HD) may be less than 20%, this difference being because people consider FAP treatable, whereas there is currently no treatment for HD." 12 With regard to prenatal testing, although 40 patients (64%) in this study stated that they would make use of prenatal testing if it was available, only 15 (24%) said that they would consider termination of pregnancy if the unborn baby was affected. This finding is similar to a previous report of a cohort of people with FAP, where 15/25 (60%) affected subjects said they would consider prenatal testing, but only four (16%) would consider the termination option.'3 People who were over 30 years, who already had an affected child or had a history of FAP related death in the family, were more likely to state that they would opt for prenatal testing and termination, and it is possible that these patients perceived FAP differently as a result of the emotional distress they associated with the disorder. In practice, none of affected subjects attending the St Mark's Polyposis Clinic in the last four years has requested prenatal testing, although only 2/62 interviewed have yet to be in a position to request this service. A marked discrepancy between statement of intent and actual uptake in clinical practice has been observed in Huntington's disease, and it is possible that this also may occur in FAP. 14 Factors influencing patient opinion may change over a period of time. Most patients under 30 years in this study do not know yet whether their children are affected, and more complete ascertainment of at risk subjects by polyposis registries should reduce death from colorectal cancer. The prenatal option may be taken up by the small group of patients who had previously refrained from having children for fear of passing on the gene.
There was a widespread feeling among the interviewees that children should not be told about polyposis until they were "old enough to understand". Most parents considered between 10 and 12 years to be the most appropriate age to introduce the subject, as they did not feel it was fair to "spring" the diagnosis at the often emotionally turbulent time of puberty. However, it is interesting that 58/62 (93%) wished to test their children at birth and withhold this information from them for a decade.
The given included (1) removing ambiguity about the disease status of their children, which some parents felt was a chronic source of stress, and (2) satisfying parental curiosity. Medical management before puberty, however, is unlikely to be altered by the information predictive testing provides, and it is difficult therefore to envisage any clear advantage for the child. Furthermore, early testing may distort parentchild or sib-sib relationships, damage the child's self esteem, remove the child's right to decide about testing at a later age, and generate unwarranted anxiety about unrelated symptoms. Who is to judge what is in the best interests of the child in this situation, and what limits, if any, should be placed on parental autonomy?
Although the Working Party's conclusions were that it is unwise to offer predictive testing for adult onset genetic conditions in childhood, but that in early onset diseases, and where medical and surgical intervention was likely to be instigated once the diagnosis was made (as in FAP), this guideline could not be adhered to, there was no general indication about when children should be tested in these conditions. Only 28 out of 49 geneticists (and 214 out of 260 paediatricians) responded positively to a questionnaire item asking whether they would test a 5 year old whose parents wanted to know his/her genetic status for FAP (compared with two geneticists and 100 paediatricians when asked the same question about HD, and 40 geneticists and 223 paediatricians regarding hyperlipidaemia).
One might conclude from this that the appropriate stance to take in the case of FAP was that testing a child at birth was not indicated, and that in general such tests should be deferred until the age at which endoscopic surveillance was to start (about 10 years) unless clinical symptoms suggest early onset of FAP polyps which can occasionally occur before 10 years. However, there are as yet no data to support any view regarding the optimum age to perform predictive testing.
In conclusion, 62 patients with FAP have been asked their views on DNA testing. The majority of patients stated that they would not consider prenatal testing and termination of pregnancy under any circumstances, but a significant minority (25%) felt that they would take up such testing. In practice, no-one, however, has yet taken up this option.
Most parents stated that they would like their children to have DNA testing at birth or in infancy, and the majority felt that the concept of FAP should be discussed with their children before puberty. Careful long term assessment and documentation of the impact of predictive testing will be needed in FAP, as in the rapidly increasing number of other single gene disorders for which DNA testing is available.
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